vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $183.1M, roughly 1.9× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -12.9%, a 26.2% gap on every dollar of revenue. On growth, Walker & Dunlop, Inc. posted the faster year-over-year revenue change (-0.4% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-680.1M). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
AMPH vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $340.0M |
| Net Profit | $24.4M | $-13.9M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -17.2% |
| Net Margin | 13.3% | -12.9% |
| Revenue YoY | -1.8% | -0.4% |
| Net Profit YoY | -35.7% | -131.0% |
| EPS (diluted) | $0.51 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $340.0M | ||
| Q3 25 | $191.8M | $337.7M | ||
| Q2 25 | $174.4M | $319.2M | ||
| Q1 25 | $170.5M | $237.4M | ||
| Q4 24 | $186.5M | $341.5M | ||
| Q3 24 | $191.2M | $292.3M | ||
| Q2 24 | $182.4M | $270.7M | ||
| Q1 24 | $171.8M | $228.1M |
| Q4 25 | $24.4M | $-13.9M | ||
| Q3 25 | $17.4M | $33.5M | ||
| Q2 25 | $31.0M | $34.0M | ||
| Q1 25 | $25.3M | $2.8M | ||
| Q4 24 | $38.0M | $44.8M | ||
| Q3 24 | $40.4M | $28.8M | ||
| Q2 24 | $37.9M | $22.7M | ||
| Q1 24 | $43.2M | $11.9M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -17.2% | ||
| Q3 25 | 13.2% | 13.6% | ||
| Q2 25 | 24.2% | 14.5% | ||
| Q1 25 | 21.9% | 2.2% | ||
| Q4 24 | 24.2% | 15.3% | ||
| Q3 24 | 29.8% | 12.8% | ||
| Q2 24 | 30.3% | 10.4% | ||
| Q1 24 | 27.9% | 6.0% |
| Q4 25 | 13.3% | -12.9% | ||
| Q3 25 | 9.0% | 9.9% | ||
| Q2 25 | 17.8% | 10.6% | ||
| Q1 25 | 14.8% | 1.2% | ||
| Q4 24 | 20.4% | 13.1% | ||
| Q3 24 | 21.1% | 9.9% | ||
| Q2 24 | 20.8% | 8.4% | ||
| Q1 24 | 25.1% | 5.2% |
| Q4 25 | $0.51 | $-0.41 | ||
| Q3 25 | $0.37 | $0.98 | ||
| Q2 25 | $0.64 | $0.99 | ||
| Q1 25 | $0.51 | $0.08 | ||
| Q4 24 | $0.74 | $1.32 | ||
| Q3 24 | $0.78 | $0.85 | ||
| Q2 24 | $0.73 | $0.67 | ||
| Q1 24 | $0.81 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $299.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.7B |
| Total Assets | $1.6B | $5.1B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $299.3M | ||
| Q3 25 | $276.2M | $274.8M | ||
| Q2 25 | $231.8M | $233.7M | ||
| Q1 25 | $236.9M | $181.0M | ||
| Q4 24 | $221.6M | $279.3M | ||
| Q3 24 | $250.5M | $179.8M | ||
| Q2 24 | $217.8M | $208.1M | ||
| Q1 24 | $289.6M | $216.5M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $1.7B | ||
| Q3 25 | $776.7M | $1.8B | ||
| Q2 25 | $757.5M | $1.8B | ||
| Q1 25 | $751.3M | $1.7B | ||
| Q4 24 | $732.3M | $1.7B | ||
| Q3 24 | $727.7M | $1.7B | ||
| Q2 24 | $713.3M | $1.7B | ||
| Q1 24 | $672.4M | $1.7B |
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.7B | $5.8B | ||
| Q2 25 | $1.6B | $4.7B | ||
| Q1 25 | $1.6B | $4.5B | ||
| Q4 24 | $1.6B | $4.4B | ||
| Q3 24 | $1.5B | $4.6B | ||
| Q2 24 | $1.5B | $4.2B | ||
| Q1 24 | $1.6B | $3.8B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-664.3M |
| Free Cash FlowOCF − Capex | $24.6M | $-680.1M |
| FCF MarginFCF / Revenue | 13.4% | -200.0% |
| Capex IntensityCapex / Revenue | 4.5% | 4.6% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-664.3M | ||
| Q3 25 | $52.6M | $-948.1M | ||
| Q2 25 | $35.6M | $-238.5M | ||
| Q1 25 | $35.1M | $-281.1M | ||
| Q4 24 | $29.0M | $129.4M | ||
| Q3 24 | $60.0M | $-202.0M | ||
| Q2 24 | $69.1M | $-237.8M | ||
| Q1 24 | $55.3M | $38.4M |
| Q4 25 | $24.6M | $-680.1M | ||
| Q3 25 | $47.2M | $-950.4M | ||
| Q2 25 | $25.0M | $-241.0M | ||
| Q1 25 | $24.4M | $-284.7M | ||
| Q4 24 | $16.6M | $116.4M | ||
| Q3 24 | $46.2M | $-204.0M | ||
| Q2 24 | $63.1M | $-241.7M | ||
| Q1 24 | $46.5M | $35.2M |
| Q4 25 | 13.4% | -200.0% | ||
| Q3 25 | 24.6% | -281.5% | ||
| Q2 25 | 14.3% | -75.5% | ||
| Q1 25 | 14.3% | -120.0% | ||
| Q4 24 | 8.9% | 34.1% | ||
| Q3 24 | 24.1% | -69.8% | ||
| Q2 24 | 34.6% | -89.3% | ||
| Q1 24 | 27.1% | 15.4% |
| Q4 25 | 4.5% | 4.6% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 0.8% | ||
| Q1 25 | 6.3% | 1.5% | ||
| Q4 24 | 6.7% | 3.8% | ||
| Q3 24 | 7.2% | 0.7% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 5.1% | 1.4% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | -28.34× | ||
| Q2 25 | 1.15× | -7.02× | ||
| Q1 25 | 1.39× | -102.07× | ||
| Q4 24 | 0.76× | 2.89× | ||
| Q3 24 | 1.48× | -7.01× | ||
| Q2 24 | 1.82× | -10.49× | ||
| Q1 24 | 1.28× | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
WD
Segment breakdown not available.
